ArticleCancer biology & therapy2015
Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
Article in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis.Aging · 2021Pooled it
- Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Pooled it
- Prognostic role of glycolysis for cancer outcome: evidence from 86 studies.Journal of cancer research and clinical oncology · 2019Pooled it
- Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis.Oncotarget · 2017Pooled it
- PKM2 is the Metabolic Checkpoint for Stemness Features in Head and Neck Cancer.Journal of Cancer · 2026Article
- GINS2 promotes oral squamous cell carcinoma progression and immune evasion by recruiting PD-L1Frontiers in immunology · 2025Article
- Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications.Current medicinal chemistry · 2024Review
- Pyruvate Kinase Differentially Alters Metabolic Signatures during Head and Neck Carcinogenesis.International journal of molecular sciences · 2023Article
- PKM2 Modulation in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2022Article
- Metabolic Regulation of Lysine Acetylation: Implications in Cancer.Sub-cellular biochemistry · 2022Review
- Discovery of Functional Alternatively SplicedCancers · 2021Article
- Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis.Cell death & disease · 2020Article
- Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.PloS one · 2020Article
- Prognostic Significance and Related Mechanisms of Hexokinase 1 in Ovarian Cancer.OncoTargets and therapy · 2020Article
- Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.Cell communication and signaling : CCS · 2019Article
- PKM2 enhances cancer invasion via ETS-1-dependent induction of matrix metalloproteinase in oral squamous cell carcinoma cells.PloS one · 2019Article
- Drugging cancer metabolism: Expectations vs. reality.International review of cell and molecular biology · 2019Review
- Tumor M2-PK: A novel urine marker of bladder cancer.PloS one · 2019Article
- The Multifarious Functions of Pyruvate Kinase M2 in Oral Cancer Cells.International journal of molecular sciences · 2018Article
- Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.Molecular cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal glucose metabolism mediated by pyruvate kinase M2 (PKM2) fuels cancer overgrowth and propagation. However, its expression and oncogenic roles in in oral squamous cell carcinoma (OSCC) remains incompletely known. Here, we aimed to investigate the expression of PKM2, its prognostic values and oncogenic functions using 7,12-dimethyl-1,2-bezan-tracene (DMBA)-induced hamster buccal pouch SCC model, primary OSCC specimens as well as in vitro cellular assays. We found that in DMBA-induced OSCC model, negative PKM2 expression was commonly observed in normal epithelial, while more PKM2 abundance was detected in hyperplasia, dysplasia and SCC. Overexpression of PKM2 in a major fraction of OSCC significantly associated with tumor size (P = 0.027), cervical node metastasis (P = 0.004) and clinical stages (P = 0.000). Patients with increased PKM2 had remarkably reduced overall and disease-free survival. Multivariate survival analysis further revealed that PKM served as a critical independent prognostic factor for patients' overall survival. Furthermore, impaired cell proliferation and migration, and reduced apoptosis were detected upon PKM2 knockdown in HN4 and HN12 cells. Taken together, our findings reveal that PKM2 is critically involved in OSCC initiation and progression probably by promoting cell proliferation and migration as well as reducing apoptosis. Its overexpression correlates with aggressive clinicopathological features and poor patients' outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.